Active Not Recruiting PHASE4 INTERVENTIONAL 1-arm
NCT06773455
Tralokinumab for Dupilumab Failures
A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab
Sponsor: LEO Pharma
Conditions
Atopic Dermatitis
Interventions
tralokinumab
Updated 1 time since 2025 Last updated: Jan 8, 2025 Started: Sep 11, 2023 Primary completion: Feb 1, 2025 Completion: Apr 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Atopic Dermatitis, this trial is ongoing. The trial is conducted by LEO Pharma and has accumulated 1 data snapshot since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Active Not Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- LEO Pharma
- Psoriasis Treatment Center of Central New Jersey
Data source: Psoriasis Treatment Center of Central New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .